BRCA2 and cancer: Based on the response to olaparib and in silico classification, we could hypothesize that the p.Met1710Leu and p.Glu1786Asp BRCA1 variants, BRCA2 variant p.Met990Lys, and PALB2 variant p.Glu907Lys are benign variants that do not respond to olaparib and are probably not involved in cancer susceptibility.